Search

Author/Creator Gonzalez, A P

1. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). (18th January 2019)

Authors:
Garcia-Sanz, R; Sureda, A; de la Cruz, F; Canales, M; Gonzalez, A P; Pinana, J L; Rodriguez, A; Gutierrez, A; Domingo-Domenech, E; Sanchez-Gonzalez, B; Rodriguez, G; Lopez, J; Moreno, M; Rodriguez-Salazar, M J; Jimenez-Cabrera, S; Caballero, M D; Martinez, C
Journal:
Annals of oncology
Issue:
Volume 30:Number 4(2019)
Page Start:
612
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search